{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:38:40Z","timestamp":1786541920304,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2025-25440216"],"award-info":[{"award-number":["RS-2025-25440216"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2025-RISE-02-003"],"award-info":[{"award-number":["2025-RISE-02-003"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54799-0","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:54:54Z","timestamp":1780390494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[68Ga]Ga-FAPI-46 PET enables non-invasive monitoring of hepatic fibrosis progression during TGF-\u03b2 inhibition"],"prefix":"10.1038","volume":"16","author":[{"given":"Yeeun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeongguk","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go-Eun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeokjin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Young","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungmin","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"54799_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cld.2008.07.007","volume":"12","author":"Y-S Lim","year":"2008","unstructured":"Lim, Y.-S. & Kim, W. R. The global impact of hepatic fibrosis and end-stage liver disease. Clin. Liver Dis. 12, 733\u2013746 (2008).","journal-title":"Clin. Liver Dis."},{"key":"54799_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1159\/000374096","volume":"33","author":"M Pinzani","year":"2015","unstructured":"Pinzani, M. Pathophysiology of liver fibrosis. Dig. Dis. 33, 492\u2013497 (2015).","journal-title":"Dig. Dis."},{"key":"54799_CR3","doi-asserted-by":"publisher","first-page":"e1499","DOI":"10.1002\/wsbm.1499","volume":"13","author":"J Berumen","year":"2021","unstructured":"Berumen, J., Baglieri, J., Kisseleva, T. & Mekeel, K. Liver fibrosis: Pathophysiology and clinical implications. WIREs Mech. Dis. 13, e1499 (2021).","journal-title":"WIREs Mech. Dis."},{"key":"54799_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q. et al. Global epidemiology of cirrhosis\u2014Aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 20, 388\u2013398 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"54799_CR5","doi-asserted-by":"crossref","unstructured":"Rockey, D. C. Hepatic fibrosis and cirrhosis. Yamada\u2019s Textb. Gastroenterol. 2000\u20132023 (2022).","DOI":"10.1002\/9781119600206.ch97"},{"key":"54799_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/cam4.1998","volume":"8","author":"K Tarao","year":"2019","unstructured":"Tarao, K. et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases\u2014Meta-analytic assessment. Cancer Med. 8, 1054\u20131065 (2019).","journal-title":"Cancer Med."},{"key":"54799_CR7","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2, 16018 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"54799_CR8","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel, K. & Sebastiani, G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2, 100067 (2020).","journal-title":"JHEP Rep."},{"key":"54799_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa, P. & Carrat, F. Liver biopsy: The best, not the gold standard. J. Hepatol. 50, 1\u20133 (2009).","journal-title":"J. Hepatol."},{"key":"54799_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","volume":"134","author":"SL Friedman","year":"2008","unstructured":"Friedman, S. L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655\u20131669 (2008).","journal-title":"Gastroenterology"},{"key":"54799_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","volume":"7","author":"SL Friedman","year":"2010","unstructured":"Friedman, S. L. Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7, 425\u2013436 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"54799_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"54799_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0168-8278(01)00142-8","volume":"35","author":"M Parola","year":"2001","unstructured":"Parola, M. & Robino, G. Oxidative stress-related molecules and liver fibrosis. J. Hepatol. 35, 297\u2013306 (2001).","journal-title":"J. Hepatol."},{"key":"54799_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633\u2013646 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"54799_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cca.2005.06.014","volume":"364","author":"S Tsukada","year":"2006","unstructured":"Tsukada, S., Parsons, C. J. & Rippe, R. A. Mechanisms of liver fibrosis. Clin. Chim. Acta 364, 33\u201360 (2006).","journal-title":"Clin. Chim. Acta"},{"key":"54799_CR16","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.3390\/biom10121666","volume":"10","author":"X Shi","year":"2020","unstructured":"Shi, X., Young, C. D., Zhou, H. & Wang, X.-J. Transforming growth factor-\u03b2 signaling in fibrotic diseases and cancer-associated fibroblasts. Biomolecules 10, 1666 (2020).","journal-title":"Biomolecules"},{"key":"54799_CR17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cells8111419","volume":"8","author":"B Dewidar","year":"2019","unstructured":"Dewidar, B., Meyer, C., Dooley, S. & Meindl-Beinker, N. TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis\u2014Updated 2019. Cells 8, 1419 (2019).","journal-title":"Cells"},{"key":"54799_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fphar.2017.00318","volume":"8","author":"BL McVicker","year":"2017","unstructured":"McVicker, B. L. & Bennett, R. G. Novel anti-fibrotic therapies. Front. Pharmacol. 8, 318 (2017).","journal-title":"Front. Pharmacol."},{"key":"54799_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/1319-3767.96445","volume":"18","author":"A Ahmad","year":"2012","unstructured":"Ahmad, A. & Ahmad, R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J. Gastroenterol. 18, 155\u2013167 (2012).","journal-title":"Saudi J. Gastroenterol."},{"key":"54799_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jcmgh.2022.12.005","volume":"15","author":"A-T Yang","year":"2023","unstructured":"Yang, A.-T. et al. Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis. Cell. Mol. Gastroenterol. Hepatol. 15, 841\u2013867 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"54799_CR21","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jcmgh.2022.12.018","volume":"15","author":"J Kim","year":"2023","unstructured":"Kim, J. & Seki, E. FAP: Not just a biomarker but druggable target in liver fibrosis. Cell. Mol. Gastroenterol. Hepatol. 15, 1018\u20131019 (2023).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"54799_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","volume":"2","author":"Y Mori","year":"2024","unstructured":"Mori, Y. et al. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). npj Imaging 2, 48 (2024).","journal-title":"npj Imaging"},{"key":"54799_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/ph14101023","volume":"14","author":"S Imlimthan","year":"2021","unstructured":"Imlimthan, S. et al. New frontiers in cancer imaging and therapy based on radiolabeled fibroblast activation protein inhibitors: A rational review and current progress. Pharmaceuticals 14, 1023 (2021).","journal-title":"Pharmaceuticals"},{"key":"54799_CR24","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1007\/s00259-024-06773-z","volume":"51","author":"Y Song","year":"2024","unstructured":"Song, Y. et al. Non-invasive visualization of liver fibrosis with [68Ga] Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation. Eur. J. Nucl. Med. Mol. Imaging 51, 3572\u20133584 (2024).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"54799_CR25","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2967\/jnumed.121.263736","volume":"63","author":"A Pirasteh","year":"2022","unstructured":"Pirasteh, A. et al. Staging liver fibrosis by fibroblast activation protein inhibitor PET in a human-sized swine model. J. Nucl. Med. 63, 1956\u20131961 (2022).","journal-title":"J. Nucl. Med."},{"key":"54799_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak, K. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696\u2013699 (1995).","journal-title":"J. Hepatol."},{"key":"54799_CR27","doi-asserted-by":"publisher","DOI":"10.2147\/HMER.S9051","author":"MH Ismail","year":"2011","unstructured":"Ismail, M. H. & Pinzani, M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepatic Med. Evid. Res. https:\/\/doi.org\/10.2147\/HMER.S9051 (2011).","journal-title":"Hepatic Med. Evid. Res."},{"key":"54799_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.14218\/JCTH.2020.00033","volume":"8","author":"H Wei","year":"2020","unstructured":"Wei, H. & Song, B. Elastography for longitudinal assessment of liver fibrosis after antiviral therapy: A review. J. Clin. Transl. Hepatol. 8, 445 (2020).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"54799_CR29","unstructured":"L\u00f3pez, A. et al. Development of novel antifibrotic agents for treating progressive liver fibrosis and related complications."},{"key":"54799_CR30","doi-asserted-by":"publisher","DOI":"10.21037\/dmr-22-9","author":"MJ Brol","year":"2022","unstructured":"Brol, M. J., Drebber, U., Luetkens, J. A., Odenthal, M. & Trebicka, J. \u201cThe pathogenesis of hepatic fibrosis: basic facts and clinical challenges\u201d\u2014Assessment of liver fibrosis: A narrative review. Dig. Med. Res. https:\/\/doi.org\/10.21037\/dmr-22-9 (2022).","journal-title":"Dig. Med. Res."},{"key":"54799_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s43162-024-00283-y","volume":"36","author":"TA Addissouky","year":"2024","unstructured":"Addissouky, T. A., Ali, M. M., Sayed, I. E. T. E. & Wang, Y. Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis. Egypt. J. Intern. Med. 36, 19 (2024).","journal-title":"Egypt. J. Intern. Med."},{"key":"54799_CR32","doi-asserted-by":"publisher","first-page":"0042","DOI":"10.34133\/bmr.0042","volume":"28","author":"S Chen","year":"2024","unstructured":"Chen, S., Zhuang, D., Jia, Q., Guo, B. & Hu, G. Advances in noninvasive molecular imaging probes for liver fibrosis diagnosis. Biomater. Res. 28, 0042 (2024).","journal-title":"Biomater. Res."},{"key":"54799_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1349-7006.2005.00103.x","volume":"96","author":"M Tojo","year":"2005","unstructured":"Tojo, M. et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-\u03b2. Cancer Sci. 96, 791\u2013800 (2005).","journal-title":"Cancer Sci."},{"key":"54799_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","volume":"347","author":"S Dooley","year":"2012","unstructured":"Dooley, S. & Ten Dijke, P. TGF-\u03b2 in progression of liver disease. Cell Tissue Res. 347, 245\u2013256 (2012).","journal-title":"Cell Tissue Res."},{"key":"54799_CR35","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/febs.13665","volume":"283","author":"I Fabregat","year":"2016","unstructured":"Fabregat, I. et al. TGF-\u03b2 signalling and liver disease. FEBS J. 283, 2219\u20132232 (2016).","journal-title":"FEBS J."},{"key":"54799_CR36","volume-title":"Seminars in Cell & Developmental Biology","author":"KW Finnson","year":"2020","unstructured":"Finnson, K. W., Almadani, Y. & Philip, A. Seminars in Cell & Developmental Biology (Elsevier, 2020)."},{"key":"54799_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2024.112448","author":"M Sultana","year":"2025","unstructured":"Sultana, M., Islam, M. A., Khairnar, R. & Kumar, S. A guide to pathophysiology, signaling pathways, and preclinical models of liver fibrosis. Mol. Cell. Endocrinol. https:\/\/doi.org\/10.1016\/j.mce.2024.112448 (2025).","journal-title":"Mol. Cell. Endocrinol."},{"key":"54799_CR38","doi-asserted-by":"publisher","first-page":"1454980","DOI":"10.3389\/fmed.2024.1454980","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Signaling pathways that activate hepatic stellate cells during liver fibrosis. Front. Med. 11, 1454980 (2024).","journal-title":"Front. Med."},{"key":"54799_CR39","doi-asserted-by":"publisher","first-page":"1389329","DOI":"10.3389\/fmed.2024.1389329","volume":"11","author":"E Shamsan","year":"2024","unstructured":"Shamsan, E. et al. The role of PI3k\/AKT signaling pathway in attenuating liver fibrosis: A comprehensive review. Front. Med. 11, 1389329 (2024).","journal-title":"Front. Med."},{"key":"54799_CR40","doi-asserted-by":"publisher","first-page":"588","DOI":"10.14218\/JCTH.2025.00029","volume":"13","author":"W Zhu","year":"2025","unstructured":"Zhu, W. et al. Exploring the therapeutic potential of TGF-\u03b2 inhibitors for liver fibrosis: Targeting multiple signaling pathways. J. Clin. Transl. Hepatol. 13, 588 (2025).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"54799_CR41","doi-asserted-by":"publisher","first-page":"1580500","DOI":"10.3389\/fphar.2025.1580500","volume":"16","author":"R Chaudhary","year":"2025","unstructured":"Chaudhary, R., Weiskirchen, R., Ehrlich, M. & Henis, Y. I. Dual signaling pathways of TGF-\u03b2 superfamily cytokines in hepatocytes: Balancing liver homeostasis and disease progression. Front. Pharmacol. 16, 1580500 (2025).","journal-title":"Front. Pharmacol."},{"key":"54799_CR42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"X-M Meng","year":"2016","unstructured":"Meng, X.-M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-\u03b2: The master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325\u2013338 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"54799_CR43","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.122.264205","volume":"63","author":"C Schmidkonz","year":"2022","unstructured":"Schmidkonz, C. et al. Fibroblast activation protein inhibitor imaging in nonmalignant diseases: A new perspective for molecular imaging. J. Nucl. Med. 63, 1786\u20131792 (2022).","journal-title":"J. Nucl. Med."},{"key":"54799_CR44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2478\/rir-2024-0021","volume":"5","author":"MT Albu","year":"2024","unstructured":"Albu, M. T., Matei, A.-E., Distler, J. H., Giesel, F. L. & Mori, Y. Fibroblast activation protein inhibitor PET\/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions. Rheumatol. Immunol. Res. 5, 152\u2013156 (2024).","journal-title":"Rheumatol. Immunol. Res."},{"key":"54799_CR45","doi-asserted-by":"publisher","first-page":"1393778","DOI":"10.3389\/fmed.2024.1393778","volume":"11","author":"P Lavis","year":"2024","unstructured":"Lavis, P., Garabet, A., Cardozo, A. K. & Bondue, B. The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis. Front. Med. 11, 1393778 (2024).","journal-title":"Front. Med."},{"key":"54799_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1021\/cbmi.5c00055","volume":"3","author":"X Hu","year":"2025","unstructured":"Hu, X. et al. Molecular imaging probes for early detection and staging of liver fibrosis. Chem. Biomed. Imaging 3, 702\u2013714 (2025).","journal-title":"Chem. Biomed. Imaging"},{"key":"54799_CR47","doi-asserted-by":"publisher","first-page":"104093","DOI":"10.1016\/j.etap.2023.104093","volume":"99","author":"D Ezhilarasan","year":"2023","unstructured":"Ezhilarasan, D. Molecular mechanisms in thioacetamide-induced acute and chronic liver injury models. Environ. Toxicol. Pharmacol. 99, 104093 (2023).","journal-title":"Environ. Toxicol. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54799-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:08:04Z","timestamp":1786540084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54799-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54799"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54799-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25061"}}